{"analyses":[{"ciLowerLimit":"0.592","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.167","groupDescription":"Teff high-WT","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.2843","paramType":"Hazard Ratio (HR)","paramValue":"0.831","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.579","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.113","groupDescription":"Teff high","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.1861","paramType":"Hazard Ratio (HR)","paramValue":"0.802","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.630","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.926","groupDescription":"ITT","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0060","paramType":"Hazard Ratio (HR)","paramValue":"0.764","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.","groupId":"OG000","lowerLimit":"17.8","upperLimit":"NA","value":"25.0"},{"comment":"Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.","groupId":"OG001","lowerLimit":"12.4","upperLimit":"NA","value":"16.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"129"}],"units":"Participants"}],"title":"Teff High-WT Population"},{"categories":[{"measurements":[{"comment":"Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.","groupId":"OG000","lowerLimit":"19.1","upperLimit":"NA","value":"25.2"},{"comment":"Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.","groupId":"OG001","lowerLimit":"12.4","upperLimit":"NA","value":"16.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"166"},{"groupId":"OG001","value":"148"}],"units":"Participants"}],"title":"Teff High Population"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.4","upperLimit":"24.2","value":"19.8"},{"groupId":"OG001","lowerLimit":"13.4","upperLimit":"17.1","value":"14.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"400"},{"groupId":"OG001","value":"400"}],"units":"Participants"}],"title":"ITT Population"}],"denoms":[{"counts":[{"groupId":"OG000","value":"400"},{"groupId":"OG001","value":"400"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.","id":"OG000","title":"Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)"},{"description":"Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.","id":"OG001","title":"Arm C (Bevacizumab+Paclitaxel+Carboplatin)"}],"paramType":"MEDIAN","populationDescription":"Teff-high WT population, defined as the Teff-high population excluding patients with activating EGFR mutation or ALK translocation. Teff-high population, defined as participants in the ITT population with Teff signature expression \\>=-1.91. ITT population, defined as all randomized patients, regardless of receipt of the assigned treatment.","reportingStatus":"POSTED","timeFrame":"Baseline until death (up to approximately 34 months)","title":"OS in Arm B Versus Arm C in Teff High-WT Population, Teff High Population, and ITT Population","type":"SECONDARY","unitOfMeasure":"Months"}